Comparative Pharmacology
Head-to-head clinical analysis: ASBRON versus BRONKOSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASBRON versus BRONKOSOL.
ASBRON vs BRONKOSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
None Documented
None Documented
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Category C
Category C
Bronchodilator
Bronchodilator